NHS Approves Revolutionary Bladder Cancer Drug
The NHS has greenlit pembrolizumab (Keytruda) for high-risk bladder cancer patients, a groundbreaking immunotherapy that could prevent recurrence and transform treatment outcomes across the UK.
The NHS has greenlit pembrolizumab (Keytruda) for high-risk bladder cancer patients, a groundbreaking immunotherapy that could prevent recurrence and transform treatment outcomes across the UK.
The NHS has greenlit pembrolizumab, a revolutionary immunotherapy drug, offering new hope for women battling advanced endometrial cancer. Discover how this treatment could transform outcomes.